Key heart and Alzheimer's disease protein imaged for first time in native stateJanuary 16, 2006Researchers for the first time have created a three-dimensional image of apolipoprotein E, a protein long associated with cardiovascular disease and more recently with Alzheimer's disease, as it appears when it is bound to fat-like substances known as lipids. Using the technique known as x-ray crystallography, scientists at the Gladstone Institute of Cardiovascular Disease (GICD) have created the highest-resolution x-ray structure of a lipoprotein particle to date. The work focuses apoE4, one of three specific forms of apolipoprotein E, commonly known as apoE. The breakthrough has already answered long-standing questions about the configuration of apoE4 in its active, or native, state. A complete understanding of the protein's functioning will be a key factor for development of future therapeutic interventions, according to the researchers.
Details of the works are reported in the January 13 edition of the Journal of Biological Chemistry. "This is the first successful use of x-ray crystallography to reveal the structure of a protein bound to lipids," explains senior author Karl Weisgraber, PhD, a senior investigator at both GICD and the Gladstone Institute of Neurological Disease (GIND). "It's crucial to understand this molecule, since it plays such a pivotal role in both cardiovascular and neurological disease. X-ray crystallography is a technique for determining the three-dimensional structure of a molecule by analyzing the x-ray diffraction patterns of crystals that make up the molecule. "The next step is higher resolution, going from the current 10 angstroms to 3.5 or better," adds Weisgraber, who is also a professor of pathology at the University of California, San Francisco. Lipid-bound proteins change their shape once they've bound to a lipid and have begun their key functions. "Until now, we've only been able to model the lipid-free structures of these proteins, and now we can begin learning about their lipid-bound forms," says lead author Clare Peters-Libeu, a GICD and GIND research scientist. "It's a huge step forward for those of us involved in the field." ApoE, and particularly apoE4, has long been studied for its role as a lipid transport protein and its involvement in cardiovascular disease. Much of the pioneering work on this molecule has been done at Gladstone since the institutes' founding in 1979, led by researchers, including Weisgraber, who had been studying the protein at the National Institutes of Health before transitioning to Gladstone. In the late 1980s, apoE emerged as a major player in neurological disease, based in part on observations made at Gladstone. Next to one's age, the greatest known risk factor for Alzheimer's disease is the gene for apoE4. ApoE4 is associated with 40-60 percent of cases of sporadic and familial Alzheimer's. Everyone inherits two copies, or alleles, of every gene, one from each parent, Weisgraber explains. As the number of apoE4 alleles increases from 0 to 2, the risk of AD increases from 20 to 90 percent, and the typical age of onset decreases from 84 years to 68 years. The presence of one apoE4 allele results in an estimated 45 percent chance of developing Alzheimer's by 85 years of age. With two apoE4 alleles, the risk increases to 50-90 percent. "Insights into the basic biology of apoE-and particularly apoE4-gained by Gladstone scientists have been invaluable in the study of Alzheimer's disease," says Peters-Libeu. "Gaining a complete, three-dimensional understanding of its configuration in its native, lipid-bound state will inevitably lead to even more insights into its role in cardiovascular and neurological disease in the years to come.\\\ Gladstone Institutes | |||||||||||||||||||||
|
Related Alzheimer Disease Current Events and Alzheimer Disease News Articles Vitamin B does not slow cognitive decline in Alzheimer's A clinical trial led by Paul S. Aisen, M.D., professor of neurosciences at the University of California, San Diego School of Medicine, showed that high-dose vitamin B supplements did not slow the rate of cognitive decline in patients with mild to moderate Alzheimer disease. Protecting patient privacy the new fashioned way Protecting patient privacy has been recognized as the duty of health-care providers for about as long as doctors have seen patients. In 1996 that duty became a legal obligation when Congress passed the Health Insurance Portability and Accountability Act. Study confirms benefit of combination therapy for Alzheimer's disease Extended treatment with Alzheimer's disease drugs can significantly slow the rate at which the disorder advances, and combination therapy with two different classes of drugs is even better at helping patients maintain their ability to perform daily activities. Seniors with type 2 diabetes may experience memory declines immediately after eating unhealthy meal Adults with type 2 diabetes who eat unhealthy, high-fat meals may experience memory declines immediately afterward, but this can be offset by taking antioxidant vitamins with the meal, according to new research from Baycrest. Memory loss linked to common sleep disorder For the first time, UCLA researchers have discovered that people with sleep apnea show tissue loss in brain regions that help store memory. Strong associations between disturbed rest/activity rhythms and mortality rates in older men A research abstract that will be presented on Wednesday at SLEEP 2008, the 22nd Annual Meeting of the Associated Professional Sleep Societies (APSS), is the first to report strong associations between disturbed rest/activity rhythms and mortality rates in older, community-dwelling (non-institutionalized) men. Hopkins researchers discover new link to schizophrenia Neuroscientists at Johns Hopkins have discovered that mice lacking an enzyme that contributes to Alzheimer disease exhibit a number of schizophrenia-like behaviors. A significant difference in the sleep disturbances among Alzheimer patients, caregivers A study published in the May 1 issue of the journal SLEEP finds that sleep disturbances among Alzheimer patients vary significantly from those of their family caregivers, and that, surprisingly, poor sleep in either the patient or caregiver is not necessarily linked to disturbed sleep in the other. Alzheimer's vaccine clears plaque but has little effect on learning and memory impairment A promising vaccine being tested for Alzheimer's disease does what it is designed to do - clear beta-amyloid plaques from the brain - but it does not seem to help restore lost learning and memory abilities, according to a University of California, Irvine study. Why fish oil is good for you It's good news that we are living longer, but bad news that the longer we live, the better our odds of developing late-onset Alzheimer's disease. More Alzheimer Disease Current Events and Alzheimer Disease News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||